A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer

Summary

The aim of the study is to test the feasibility \& loco-regional control rate by combining high precision SBRT with chemotherapy in stage III NSCLC in tumor/lymph nodes if tumors/lymph node size with ≤ 6cms in size.

Eligibility

Inclusion Criteria:

1. Aged 18 or above and less than 75 years.
2. Histologically proven non-small cell lung cancer.
3. Stage T1-4, N1-3, M0 with maximum tumor size less than 6 cms and ≤ 3 stations of largest lymph node size less than 4 cms.
4. ECOG status 0-1.
5. Available to attend long term follow- up.
6. Written informed consent for treatment.

Exclusion Criteria:

1. Metastatic disease.
2. Tumor size \> 6cm.
3. Involved Lymph node size greater than 4 cms \& more than 3 station of lymph nodes involved.
4. Patients with superior vena cava obstruction.
5. Tumor invading/encasing the proximal bronchial tree/, esophagus, pericardium.
6. Previous radiotherapy to thorax.
7. Small cell histology.
8. Age\< 18 or \> 75 years.
9. Patients on anticoagulant therapy \& ultra-central cavitary tumors.
10. Poor performance status ECOG 2-3.
11. Immunocompromised states.
12. Viral Markers negative.
13. Pregnant women

Conditions3

Browse More Trials